RxDoctor Payments Data

Allan Torres, MD

Urology · San Juan, PRNPI 1982690046

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,424 of the $3,921 with a category attached, or 87.3%. 14 manufacturers reported payments, led by Boston Scientific at 36.2% of the total. Reporting peaked in 2019 at $1,093 and has fallen 70.0% since, to $328 in 2025.

$3,921in general payments, 2019–2025

Across 42 payments — averaging $93.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Teleflex LLC$844
  • Verity Pharmaceuticals Inc.$245
  • Merck$224
  • Johnson & Johnson$201
  • BD$130
  • plus $860 from 8 others

What the payments were for

  • Travel & lodging$49813%
  • Food & beverage$3,42487%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,921 in reported general payments places this provider in the 65th percentile of 122 urology providers in Puerto Rico.

See all urology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$27,158
Medicare patients
98
Services billed
201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide12$180,213
TrelstarTriptorelin Pamoate88$92,677
Lupron DepotLeuprolide Acetate40$80,506
MyrbetriqMirabegron149$69,895
Alfuzosin Hcl ErAlfuzosin Hcl1,125$17,767
Trospium Chloride71$4,490
Tamsulosin Hcl368$3,662
Oxybutynin Chloride ErOxybutynin Chloride209$3,565
Sildenafil Citrate67$2,216
Humalog Mix 75-25Insulin Lispro Protamin/Lispro23$2,103
Finasteride106$1,706
Dutasteride51$1,568
Ketorolac Tromethamine36$1,112
Ciprofloxacin Hcl111$773
Bicalutamide25$743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$201$180,21312 claims
Verity Pharmaceuticals Inc.Trelstar$245$92,67788 claims
AbbVieLupron Depot$100$80,50640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 122 urology providers in Puerto Rico.

Other urology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →